Study Estimates Worldwide Prevalence of 25 Adult Cancers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 2
Volume 11
Issue 2

LYON, France-A study from the International Agency for Research on Cancer (IARC) shows a higher cancer prevalence in the developed world, primarily because of longer life expectancy in richer countries (Int J Cancer 97:72-81, 2002).

LYON, France—A study from the International Agency for Research on Cancer (IARC) shows a higher cancer prevalence in the developed world, primarily because of longer life expectancy in richer countries (Int J Cancer 97:72-81, 2002).

The study examined the prevalence of 25 adult cancers for 11 world areas using data from IARC for developing countries, US SEER, and EUROCARE I. The study described the number of cancer cases diagnosed between 1986 and 1990 among individuals aged 15 or older who were still alive at the end of 1990.

Lead author Paola Pisani, reported the highest cancer prevalence in North America at 1.5%. Western Europe and Australia/New Zealand had a prevalence of 1.2% and 1.1%, respectively, followed by Japan at 1%, Eastern Europe at 0.7%, and Latin American and the Caribbean at 0.4%. The lowest prevalence (0.2%) was found in sub-Saharan Africa, the Middle East and Northern Africa, and Southeastern and South Central Asia.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content